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Abstract
Background Basophils, eosinophils and monocytes may be involved in BCG-induced immune responses and be associated 
with outcomes of bladder cancer patients receiving intravesical BCG. Our objective was to explore the association of baseline 
counts of basophils, eosinophils and monocytes with outcomes of patients with high-grade T1 bladder cancer receiving a 
standard course of intravesical BCG.
Methods We retrospectively reviewed medical records of patients with primary T1 HG/G3 bladder cancer. After re-TURBT, 
patients were treated with a 6-week course of intravesical BCG induction followed by intravesical BCG every week for 
3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months from initiation of therapy The analysis of potential risk factors for recur-
rence, muscle invasion and cancer-specific and overall survival was performed using univariable Cox regression models. 
Those factors that presented, at univariate analysis, an association with the event at a liberal p < 0.1, have been selected for 
the development of a multivariable model.
Results A total of 1045 patients with primary T1 HG/G3 were included. A total of 678 (64.9%) recurrences, 303 (29.0%) 
progressions and 150 (14.3%) deaths were observed during follow-up. Multivariate analysis showed that logarithmic trans-
formation of basophils count was associated with a 30% increment in the hazard of recurrence per unit increase of logarith-
mic basophils count (HR 1.30; 95% confidence interval 1.09–1.54; p = 0.0026). Basophil count modeled by quartiles was 
also significantly associated with time to recurrence [second vs. lower quartile HR 1.42 (1.12–1.79); p = 0.003, third vs. 
lower quartile HR 1.26 (1.01–1.57); p = 0.041; upper vs. lower quartile HR 1.36 (1.1–1.68); p = 0.005]. The limitations of 
a retrospective study are applicable.
Conclusion Baseline basophil count may predict recurrence in BCG-treated HG/G3 T1 bladder cancer patients. External 
validation is warranted.
Keywords Bladder cancer · Basophils · BCG
Introduction
In 2012, bladder cancer was diagnosed in 430,000 people 
and caused 165,000 deaths worldwide [1]. The incidence 
has increased in some eastern European and developing 
countries, while it has decreased in most Western countries 
[2], although some areas in Western Europe (e.g. province 
of Naples, Italy [3]) present an unusually high incidence 
and prevalence. Patients with non-muscle invasive disease 
receiving an adequate course of intravesical Bacillus Cal-
mette–Guérin (BCG) show a 1-and 5-year recurrence rate 
of approximately 25 and 40%, respectively [4]. After BCG 
approval by the FDA in 1990, no other intravesical treat-
ment has proved to be superior to BCG, but a large body 
of evidence have been collected about the immunological 
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mechanisms underlying its effectiveness in this setting [5]. 
In patients with high-grade T1 tumors receiving adjuvant 
BCG, the risk of recurrence can be modeled using multiple 
clinical and pathologic variables, which include tumor size, 
age and presence of carcinoma in situ [4], peripheral blood 
neutrophil-to-lymphocyte ratio and presence of high-grade 
T1 on re-Transurethral Resection of bladder tumor (TURBT) 
[6], obesity [7], as well as lymph-vascular invasion [8]. 
Importantly, while the predictive value of neutrophil to lym-
phocyte ratio has been widely confirmed in bladder cancer 
patients treated with BCG [9], the putative predictive value 
of other white blood cells assessed in the peripheral blood, 
which may be involved in BCG-induced immune responses, 
is yet to be adequately investigated.
On the basis of the alleged mechanisms of action of BCG 
[5], we hypothesized that baseline levels of monocytes, 
basophils and eosinophils measured in the peripheral blood 
at the time of first TURB could be associated with clinical 
outcomes in G3/HG (grade 3/high grade) T1 bladder cancer 
patients receiving intravesical BCG. Data of a large, multi-
institutional, retrospective cohort that had been assessed 
elsewhere for a different purpose [6] were re-analyzed to 
explore this hypothesis.
Patients and methods
Patients and methods
The patient population and the methods used to collect 
the data analyzed here have already been described [6]. 
Briefly, patients were included in this cohort if they had 
pathologically proven T1 HG/G3 at first TURBT. Patients 
underwent re-TURBT performed within 4–6 weeks after the 
first TURBT to maximally resect residual tumor. Patients 
included in this cohort had no residual tumor or non-muscle 
invasive residual tumor at re-TURBT and were treated with 
a 6-week course of intravesical BCG induction followed 
by intravesical BCG every week for 3 weeks given at 3, 
6, 12, 18, 24, 30 and 36 months from initiation of therapy. 
Patients with signs of acute infection or incomplete data 
were excluded from this study cohort. In the analysis per-
formed here, only patients with full blood count data per-
formed before TURBT, including absolute while blood cell, 
absolute neutrophil, absolute lymphocyte, absolute eosino-
phil, absolute basophil and absolute monocyte counts were 
included.
The following data observed within 2 weeks of first 
TURBT were retrieved: age, gender, smoking history (cat-
egorized as current smoker, non-smoker or former smoker), 
SED (sedimentation) rate, C reactive protein (CRP), serum 
albumin, body mass index, full blood count. The follow-
ing pathology findings related to TURBT and re-TURBT 
were retrieved: pathology grade and stage, maximum tumor 
size, presence of multiple tumors of the bladder, presence 
of concomitant carcinoma in situ, presence of HG/G3 dis-
ease at re-TURBT, lympho-vascular invasion (LVI). The 
following data about cancer history were retrieved: date of 
first TURBT, date of re-TURB, date of first progression (if 
patient had progressed), date of first recurrence (if patient 
had recurred), date and cause (Author query: Please consider 
rephrasing the following sentence: date of first TURBT, date 
of re-TURB, date of first progression (if patient had pro-
gressed), date of first recurrence (if patient had recurred), 
date and cause of (if patient had died), date of last follow-
up.)of (if patient had died), date of last follow-up. Maximum 
tumor size was defined as the longest diameter of the larg-
est lesion. The TNM system of the Union for International 
Cancer Control and the 1973 World Health Organization 
grading classification were followed by the local pathologist 
for the pathology analysis. Recurrent disease was defined 
as any disease recurrence, both non muscle-invasive and 
muscle-invasive, diagnosed during follow-up. Progressive 
disease was defined as muscle-invasive disease diagnosed 
during follow-up. The endpoints were time to recurrent dis-
ease (TTR), time to progressive disease (TTP), overall- and 
cancer-specific survival (OS and CSS).
Statistical analysis
Descriptive statistics have been used to characterize the 
overall cohort with respect to the main demographical and 
clinical characteristics. Median follow-up was computed 
according to the reverse Kaplan–Meier. Survival curves 
were estimated with the Kaplan–Meier method. The analy-
sis of potential risk factors for recurrence, muscle invasion 
and overall survival was performed using univariable Cox 
regression models. Those factors that presented, at univari-
ate analysis, an association with the event at a liberal p < 0.1, 
have been selected for the development of a multivariable 
model. The proportional hazard (PH) assumption was tested 
using the Schoenfeld residuals. When evidence of violation 
of PH assumption was found a weighted Cox regression 
model was estimated using the method described in litera-
ture [10], which provides unbiased average HR estimates 
irrespective of proportionality of hazards. A supportive 
analysis was conducted considering the overall recurrence 
rate at the landmark time points of 24, 36 and 48 months. 
Patients with a shorter follow-up were excluded from this 
analysis if they had not recurred during follow-up. Baso-
philes count was modeled using both the observed quartiles 
and logarithmic transformation, thus allowing for its nonlin-
ear association with time-to-event variables. For all statisti-
cal comparisons, a level of p value < 0.05 was accepted as 
statistically significant. All analyses were performed using 
r version 3.5.1 (http://www.r-proje ct.org).
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Results
Patient population
A total of 1045 patients with primary T1 HG/G3 treated 
between January 1, 2002 and December 31, 2012 at 13 
academic institutions were eligible to be included in this 
analysis. Main characteristics of the study population are 
depicted in Table 1. Median follow-up was 26 months 
[interquartile range (IQR) 10–47 months]. Three hundred 
and three (29%) patients received the full 36-month BCG 
treatment. A total of 678 (64.9%) exhibited recurrence, 
303 exhibited (29.0%) progressions, and 150 (14.3%) all-
cause deaths and 77 bladder cancer-related deaths (7.3%) 
were observed during follow-up.
Results of univariate and multivariate analysis
At univariate analysis, absolute monocytes and eosinophil 
counts were not associated with either time to recurrence, 
time to progression or overall survival, while logarithmic 
transformation of basophils count showed a 30% increment 
in the hazard of recurrence per unit increase (HR 1.30; 95% 
confidence interval 1.10–1.53; p = 0.0018). A significant 
association between high basophil count and shorter time 
to recurrence was also found for the second vs. the first and 
the fourth vs. the first quartile of the baseline basophil count 
distribution (Table 2). The median recurrence-free survival 
time in the four baseline basophil count quartiles were the 
following: 43 months (95% CI 33–52 months), 22 months 
(95% CI 16–35 months), 31 months (95% CI 24–46 months) 
and 22 months (95% CI 17–27 months) (Fig. 1). No asso-
ciation of baseline basophil count was reported with over-
all- and cancer-specific survival (data not shown). Baseline 
basophil count was associated with time to progression at 
univariate analysis when analyzed as a continuous, log-
transformed variable (HR 1.32; 95% confidence interval 
1.02–1.71; p = 0.0296), but not as a categorial variable 
defined by quartiles (data not shown). 
Multivariate analysis confirmed that logarithmic transfor-
mation of basophils count was associated with a 30% incre-
ment in the hazard of recurrence per unit increase (HR 1.30; 
95% confidence interval 1.09–1.54; p = 0.0026). Based on 
this finding, we modeled basophil count using quartiles and 
explored the association with recurrence using the lower 
quartile as reference for the others. The three upper quar-
tiles were all significantly and consistently associated with 
increased risk of recurrence at multivariate analysis when 
compared to the lower quartile [second vs. lower quartile 
HR 1.42 (1.12–1.79); p = 0.003; third vs. lower quartile HR 
1.26 (1.01–1.57); p = 0.041; upper vs. lower quartile HR 
1.36 (1.1–1.68); p = 0.005) (Table 2), but it was not associ-
ated with time to progression or overall survival (data not 
shown). Univariate and multivariate logistic-regression 
analysis showed that the odds of having a recurrence within 
36 months were more than double in patients in the second, 
third and fourth quartiles vs. the first (see Table 3). Similar 
results were obtained considering the overall recurrence rate 
at 24 and 48 months (data not shown).
Discussion
Adaptive T-cell mediated immune responses have been 
classically divided in type 1 (Th1) and type 2 (Th2) T 
helper cell responses [11]. Th1 vs. Th2 polarization has 
been related to different cytokine patterns, with the former 
being associated with secretion of interferon (IFN)-gamma, 
interleukin (IL)-2 and tumor necrosis factor (TNF)-beta, 
Table 1  Characteristics of the patient population
BMI body mass index, Cis carcinoma in  situ, LVI lymph vascular 
invasion, SED sedimentation rate, CRP C reactive protein
a Data are expressed as either median [25th; 75th percentile] (min to 
max) or absolute frequencies (percentages)
Overall cohort (n = 1045)a
Age (years) 70 [64; 77] (29–91)
Gender; female 182 (17.4)
BMI (kg/m2) 27 [23.8; 29] (16–38.1)
Smoking status
 Yes 484 (46.3)
 No 295 (28.2)
Former 266 (25.5)
Multifocality 460 (44)
Tumor size > 3 cm 673 (64.5)
Concomitant Cis 149 (14.3)
LVI 165 (15.8)
LVI at re-turb 59 (5.6)
Residual disease at re-turb 257 (24.6)
SED (mm/h) 13 [8; 22] (1–109)
CRP (mg/dL) 2 [0.7; 4.6] (0–33.8)
Albumin (g/dL) 4.2 [3.9; 4.5] (1.1–7.1)
Neutrophils/lymphocytes ratio 2.9 [1.9; 4.6] (0.5 to 22.2)
Monocytes count (× 103/µL) 0.53 [0.4; 0.76] (0.01–6.7)
Eosinophils count  (103/µL) 0.18 [0.1; 0.29] (0–2)
Basophils count  (103/µL)
1° quartile [min to 0.01] 278 (26.6)
2° quartile [0.01–0.03] 202 (19.3)
3° quartile [0.03–0.05[ 266 (25.5)
4° quartile [0.05 to max] 299 (28.6)
Platelets count (× 10^3/µL) 232 [193; 284.5] (40–486)
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which stimulate phagocytosis, and the latter being associ-
ated with IL-4, IL-5, IL-6, IL-10 and IL-13, which stimu-
late antibody production (including antibodies belonging to 
the IgE class), but inhibit several functions of phagocytic 
cells and can exert an anti-inflammatory effect. Although 
type 2 immune reactions have been discovered to be useful 
not only in fighting helminthic worm infections, but also in 
suppressing type 1-driven autoimmune disease, neutralizing 
toxins and maintaining metabolic homeostasis, they are also 
associated with a variety of morbid conditions related to 
atopic reactions, including asthma, anaphylaxis and rhini-
tis [11]. In the particular case of intravesical BCG therapy 
in early bladder cancer, a large body of evidence suggests 
that a Th2 cell-polarized response is associated with BCG 
ineffectiveness, while type 1 helper T cells induce BCG-
mediated immune responses capable of anti-tumor activity 
[12] [13] [14] [15]. Urine levels of selected Th1 and Th2 
cytokines have been successfully assessed as biomarkers of 
response to BCG treatment. Increased urine levels of IL-2 
[16], a Th1 cytokine secreted by CD4+ T cells that exerts its 
main effects by stimulating cytotoxic CD8+ lymphocyte and 
macrophage activity, have been reported in BCG responders 
vs. non-responders. A higher interleukin-6/10 ratio has been 
associated with increased risk of recurrence of BCG-treated 
patients, while another study found that IL-2 urine levels 
showed an earlier peak than IL-10 levels in responders vs. 
non responders.
Basophils may have a role in BCG-treated bladder cancer 
patients because of their ability to facilitate Th2 polariza-
tion by secreting IL-4 and skewing antigen-presenting cells 
towards a type 2 response [17]. In fact, studies in mouse 
models have shown that depletion of basophils can impair 
Th2 polarization [18] and that Th2 responses to cysteine pro-
tease are mediated by a complex interplay between migra-
tory dermal dendritic cells (DCs) and basophils positive for 
interleukin 4 (IL-4) via ROS-mediated signaling [19].
Although literature data support the non-redundant role 
of basophils in Th2 responses [20], their significance in solid 
Table 2  Univariate and 
multivariate analysis of 
predictors of time to recurrence
Bold values indicate significant correlations at the level of 0.05
BMI body mass index, Cis carcinoma in situ, LVI lymph vascular invasion, SED sedimentation rate, CRP C 
reactive protein
Time to recurrence
Univariate Multivariate
HR [95% CI] p value HR [95% CI] p value
Age (years) 0.99 [0.99–1] 0.161
Gender; female 1.24 [1.03–1.5] 0.023 1.06 [0.88–1.29] 0.53
BMI (kg/m2) 1.17 [1.15–1.2] < 0.001 1.13 [1.1–1.15] < 0.001
Smoking status
 Yes Ref – Ref –
 No 0.95 [0.8–1.13] 0.572 1 [0.83–1.2] 0.964
Former 0.56 [0.46–0.68] < 0.001 0.62 [0.5–0.77] < 0.001
Multifocality 1.32 [1.13–1.53] < 0.001 1.1 [0.95–1.29] 0.209
Tumor size > 3 cm 1.3 [1.11–1.53] 0.001 1.16 [0.98–1.37] 0.083
Concomitant Cis 1.19 [0.97–1.47] 0.095 1.08 [0.87–1.33] 0.501
LVI at TURB 1.53 [1.26–1.85] < 0.001 1.36 [1.12–1.66] 0.002
LVI at re-TURB 2.9 [2.21–3.8] < 0.001 2.07 [1.56–2.76] < 0.001
Pathologic grade at re-turb G3 1.74 [1.48–2.06] < 0.001 1.36 [1.14–1.62] < 0.001
SED (mm/h) 1.01 [1–1.01] 0.002 1 [0.99–1] 0.24
CRP (mg/dL) 1.03 [1.01–1.04] 0.001 1.01 [0.99–1.03] 0.22
Albumin (g/dL) 1.07 [0.93–1.23] 0.335
Neutrophils/lymphocytes ratio 1.16 [1.14–1.19] < 0.001 1.12 [1.09–1.15] < 0.001
Monocytes count (× 103/µL) 0.89 [0.77–1.03] 0.112
Eosinophils count (× 103/µL) 1 [0.71–1.41] 0.999
Basophils count (× 103/µL)
 1° quartile [min to 0.01] Ref – Ref –
 2° quartile [0.01–0.03] 1.38 [1.1–1.72] 0.005 1.42 [1.12–1.79] 0.003
 3° quartile [0.03–0.05] 1.11 [0.9–1.38] 0.334 1.26 [1.01–1.57] 0.041
 4° quartile [0.05 to max] 1.33 [1.09–1.64] 0.006 1.36 [1.1–1.68] 0.005
Platelets count (×  103/µL) 1.13 [1.02–1.25] 0.017 1.11 [0.99–1.23] 0.069
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malignancies has been poorly investigated. One preclinical/
clinical study conducted in 85 pancreatic ductal adenocar-
cinoma patients and in a mouse model [21] reported three 
main findings that clarify the role of basophils identified in 
tumor-draining lymph nodes in inducing Th-2 responses. 
First, IL-4 levels were higher in tumor-draining vs. non-
tumor draining lymphnodes and the lymph node fraction 
containing basophils also had higher IL-4 levels. Further-
more, IL-4 mRNA expression correlated with basophil pres-
ence demonstrated at immunohistochemistry, supporting the 
role of basophils as source of IL-4 in tumor tumor-draining 
lymphnodes. Second, the percentage of basophils in tumor-
draining lymphnodes positively correlated with the ratio of 
GATA-3+/T-bet+ lymphoid infiltrates, which is indicative 
of Th2 polarization [22]. Third, multivariate analysis in 36 
patients with available survival data stratified for known 
prognostic variables showed that the percentage of basophils 
in tumor-draining lymphnodes was independently predic-
tive of disease-free survival (p = 0.02, HR = 11.07, range 
1.38–88.60) and overall survival (p = 0.04, HR = 8.51, range 
1.04–69.33). All the limitations of a retrospective study are 
applicable to our work. Specifically, the study design could 
have been improved by collecting basophil count at various 
time points and by using more stringent exclusion criteria, 
e.g. by excluding patients affected by parasitic infections or 
other conditions that may affect basophil count [23]. The 
use of different laboratory equipment and methods among 
the participating centers may also constitute a bias. We 
noted that basophil count analyzed both as a logarithmic-
transformed continuous variable and when modeled by 
using quartiles was associated with time to recurrence at 
multivariate analysis, although the third quartile appeared 
to have better time to recurrence than the second quartile, as 
shown in Fig. 1. This finding does not emerge when all the 
available predictive variables are included in the multivariate 
analysis (Table 2) and is probably the result of confound-
ing factors. Nevertheless, as the underlying biology of the 
relationship between basophils and BCG effectiveness—if 
it does exist—is unknown, we cannot exclude that; further 
studies may identify separate basophil count intervals that 
are associated with worse time to recurrence. We hypothe-
size that the reported findings are consistent with the known 
role of basophils in mediating Th2 polarization, which 
gives biological plausibility to the statistically significant 
association reported. In fact, patients with high basophils 
before receiving BCG(e.g. > 10 basophils/ml) may benefit 
Fig. 1  Recurrence free survival 
by basophils quartiles
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from a personalized therapeutic strategy to increase BCG 
effectiveness. IL-4 may be a candidate druggable target in 
these patients. Anti IL-4 available agents include anti IL-4 
monoclonal antibodies [24], a soluble recombinant human 
IL-4 receptor [25] or a variant form of IL-4 [26]. Even if 
obtained in a large data-set, we recognize that the findings 
reported here may simply be the result of some bias. If con-
firmed by independent investigators, our discovery may 
unveil novel therapeutic options for a neglected condition 
that has recorded little improvements in therapy over the 
past 30 years.
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Table 3  Univariate and 
multivariate analysis of 
predictors of recurrence within 
36 months of follow-up
Bold values indicate significant correlations at the level of 0.05
BMI body mass index, Cis carcinoma in situ, LVI lymph vascular invasion, SED sedimentation rate, CRP C 
reactive protein
Recurrence within 36 months of follow-up
Univariate Multivariate
HR [95% CI] p value HR [95% CI] p value
Age (years) 0.99 [0.98–1.01] 0.277
Gender; female 1.65 [1.11–2.47] 0.014 2.03 [1.12–3.67] 0.02
BMI (kg/m2) 1.51 [1.43–1.6] < 0.001 1.43 [1.33–1.53] < 0.001
Smoking status
 Yes Ref Ref
 No 0.97 [0.69–1.36] 0.867 1.14 [0.68–1.91] 0.619
Former 0.45 [0.32–0.63] < 0.001 0.74 [0.44–1.25] 0.267
Multifocality 1.54 [1.17–2.04] 0.002 1.42 [0.92–2.17] 0.112
Tumor size > 3 cm 1.54 [1.16–2.05] 0.003 1.65 [1.05–2.6] 0.031
Concomitant Cis 1.3 [0.87–1.93] 0.206
LVI 1.98 [1.31–3.01] 0.001 1.84 [1–3.4] 0.052
LVI at re-TURB n.a. n.a
Pathologic grade at re-turb G3 2.85 [1.98–4.1] < 0.001 2.12 [1.23–3.65] 0.007
SED (mm/h) 1.02 [1.01–1.04] < 0.001 1 [0.99–1.02] 0.748
CRP (mg/dL) 1.06 [1.02–1.09] 0.002 1.01 [0.96–1.06] 0.737
Albumin (g/dL) 1.13 [0.88–1.46] 0.332
Neutrophils/lymphocytes ratio 3.46 [2.9–4.14] < 0.001 3.13 [2.54–3.85] < 0.001
Monocytes count (× 103/µL) 0.74 [0.58–0.94] 0.014 1.15 [0.77–1.73] 0.487
Eosinophils count (× 103/µL) 0.93 [0.48–1.8] 0.826
Basophils count (× 103/µL)
 1° quartile [min to 0.01] Ref Ref
 2° quartile [0.01–0.03] 1.56 [1.03–2.36] 0.038 2.87 [1.51–5.45] 0.001
 3° quartile [0.03–0.05] 1.14 [0.78–1.67] 0.487 2.14 [1.19–3.85] 0.011
 4° quartile [0.05 to max] 1.43 [0.99–2.07] 0.058 2.85 [1.52–5.36] 0.001
Platelets count (× 103/µL) 1.02 [1–1.04] 0.064 1.01 [0.98–1.04] 0.433
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